Evidence map›Paper›PMID 41310174›Full record

ArticleScientific reports2025

Integrated genomic-transcriptomic analysis of clavulanic acid production in differentially productive Streptomyces clavuligerus strains.

Junpyo Gong, Jeong Sang Yi, Seungchan An, Hang Su Cho, Chang Hun Shin, Hyung-Jin Won, Namil Lee, Yongjae Lee, Byung-Kwan Cho, Minsoo Noh and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Junpyo Gong *Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Jeong Sang Yi *Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Seungchan AnNatural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Hang Su ChoNatural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Chang Hun ShinResearch Institute of CKD BiO, Ansan, 15604, Republic of Korea.
Hyung-Jin WonResearch Institute of CKD BiO, Ansan, 15604, Republic of Korea.
Namil LeeDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
Yongjae LeeDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
Byung-Kwan ChoDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
Minsoo NohNatural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. minsoonoh@snu.ac.kr.
Yeo Joon YoonNatural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. yeojoonyoon@snu.ac.kr.

Funding

Ministry of Education RS-2022-NR075139Ministry of Science and ICT RS-2025-02263193Ministry of Science and ICT, South Korea RS-2021-NR056596Ministry of Science and ICT, South Korea RS-2022-NR067344National Research Foundation of Korea RS-2022-NR070550National Research Foundation of Korea RS-2024-00399364
6 · The paper itself

Abstract

Clavulanic acid (CA) is a specific metabolite that inhibits β-lactamases, which inactivate β-lactam antibiotics, therefore reinstating the activity of β-lactams against β-lactamase-producing pathogens, and surmounting β-lactam resistance. While extensive efforts have been made to optimize CA production through random mutagenesis, these approaches often introduce deleterious mutations, limiting further yield improvements. In this study, whole-genome sequencing, time-resolved transcriptomics, and independent component analysis (ICA)-based gene co-expression network analysis were employed to elucidate the genetic and transcriptomic factors underlying enhanced CA production in mutant Streptomyces clavuligerus strains developed through ultraviolet-induced random mutagenesis. By analyzing strains with varying CA productivities and correlating genomic and transcriptomic changes, we identified multiple candidate mutations, key transcriptional regulators, and metabolic pathways influencing CA yield. Notable findings include large plasmid deletions, an enrichment of mutations in secondary metabolite biosynthesis and regulatory genes, and metabolic shifts redirecting amino acid and carbon flux toward CA biosynthetic pathways. ICA revealed gene modules directly associated with CA biosynthesis, precursor supply, and transcriptional regulation. This integrative approach generated a comprehensive paired genomic-transcriptomic dataset for CA production. The insights gained offer targeted strategies for rational strain engineering, advancing more efficient and sustainable antibiotic production.

Indexed as

Clavulanic AcidStreptomycesTranscriptomeBiosynthetic PathwaysGene Expression ProfilingGene Expression Regulation, BacterialGenome, BacterialGenomicsMetabolic Networks and PathwaysMutagenesisMutationClavulanic Acid

Identifiers

PMID41310174
PMCPMC12749726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.